Lee Kaplan, M.D., discusses the metabolic case for survodutide | ADA 2026

Survodutide, Boehringer Ingelheim's investigational dual glucagon/GLP-1 receptor agonist, made headlines at the American Diabetes Association 2026 Scientific Sessions, with phase 3 data suggesting its metabolic benefits extend beyond the scale.

In SYNCHRONIZE-1, a 76-week trial in adults with obesity without type 2 diabetes, survodutide achieved mean body weight reductions of 12.2% to 13.0% versus 5.4% with a placebo. Nearly 29% of patients on the 6 mg dose lost at least 20% of their body weight. But the more striking findings came from a prespecified MRI substudy. At the 6 mg dose, liver fat fell by 63.1% and visceral fat by 34%, while lean body volume dropped by just 9.8%, meaning more than 89% of tissue lost was fat, not muscle.

In a separate 48-week phase 3 trial, SYNCHRONIZE-MASLD, survodutide was tested specifically in patients with obesity and metabolic dysfunction–associated steatotic liver disease. Results were compelling: up to 84.2% of treated patients achieved at least a 30% reduction in liver fat, and 61% reached liver fat normalization (defined as fat content below 5%), compared with just 5.7% on placebo.

SYNCHRONIZE-1 presenting author Lee M. Kaplan, M.D., Ph.D., director of the Obesity and Metabolism Institute at Massachusetts General Hospital, and colleagues noted that liver fat reductions appeared earlier than would be expected from weight loss alone and were more pronounced at the higher dose despite similar weight reductions across doses. This points to a direct hepatic mechanism tied to glucagon receptor agonism.

In this interview with Managed Healthcare Executive^®, Kaplan discusses how the organ-selective reductions in liver and visceral fat seen with survodutide could reshape how clinical value is defined in obesity pharmacotherapy and strengthen the coverage case as non-invasive diagnostic tools make earlier MASLD identification increasingly feasible.